Search research articles
Contact Us
Filters
Showing results (41-50 of 56) with videos related to
Page
of 6
Sort By:
Nature Cancer
|
August 29, 2024
A targetable type III immune response with increase of IL-17A expressing CD4<sup>+</sup> T cells is associated with immunotherapy-induced toxicity in melanoma
Florentia Dimitriou, Phil F Cheng, Annalisa Saltari, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 6, 2021
Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response
Florentia Dimitriou, Anne Zaremba, Clara Allayous, et al.
Journal of Translational Medicine
|
October 26, 2023
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
Domenico Mallardo, Rachel Woodford, Alexander M Menzies, et al.
Scientific Reports
|
November 2, 2023
Sinonasal mucosal melanoma treatment response assessment to immune checkpoint inhibitors using hybrid positron emission tomography imaging
Alexander Maurer, Nathalie A Gstrein, Florentia Dimitriou, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 14, 2024
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma
Lea Jessica Albrecht, Florentia Dimitriou, Piyush Grover, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 8, 2024
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors
Florentia Dimitriou, Marlana M Orloff, Erica C Koch Hein, et al.
Journal for Immunotherapy of Cancer
|
October 12, 2021
Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
Briana Rose Halle, Allison Betof Warner, Farzana Y Zaman, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 26, 2024
Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy
Amelia M Taylor, Janet McKeown, Florentia Dimitriou, et al.
Journal for Immunotherapy of Cancer
|
November 28, 2025
International real-world study of combination immunotherapy sequences in metastatic melanoma
Mora Guardamagna, Sarah E Lochrin, James William Smithy, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 4, 2024
Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy
Rachel Woodford, Janet McKeown, Lotte L Hoeijmakers, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 56) with videos related to
Sort By:
Page
of 6
Nature Cancer
|
August 29, 2024
A targetable type III immune response with increase of IL-17A expressing CD4<sup>+</sup> T cells is associated with immunotherapy-induced toxicity in melanoma
Florentia Dimitriou, Phil F Cheng, Annalisa Saltari, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 6, 2021
Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response
Florentia Dimitriou, Anne Zaremba, Clara Allayous, et al.
Journal of Translational Medicine
|
October 26, 2023
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
Domenico Mallardo, Rachel Woodford, Alexander M Menzies, et al.
Scientific Reports
|
November 2, 2023
Sinonasal mucosal melanoma treatment response assessment to immune checkpoint inhibitors using hybrid positron emission tomography imaging
Alexander Maurer, Nathalie A Gstrein, Florentia Dimitriou, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 14, 2024
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma
Lea Jessica Albrecht, Florentia Dimitriou, Piyush Grover, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 8, 2024
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors
Florentia Dimitriou, Marlana M Orloff, Erica C Koch Hein, et al.
Journal for Immunotherapy of Cancer
|
October 12, 2021
Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
Briana Rose Halle, Allison Betof Warner, Farzana Y Zaman, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 26, 2024
Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy
Amelia M Taylor, Janet McKeown, Florentia Dimitriou, et al.
Journal for Immunotherapy of Cancer
|
November 28, 2025
International real-world study of combination immunotherapy sequences in metastatic melanoma
Mora Guardamagna, Sarah E Lochrin, James William Smithy, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 4, 2024
Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy
Rachel Woodford, Janet McKeown, Lotte L Hoeijmakers, et al.
Page
of 6